CAMBRIDGE, Mass., Dec. 1 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has filed a preliminary prospectus supplement to its shelf registration statements on Form S-3 for a proposed public offering of 8,800,000 shares of its common stock and warrants to purchase 8,800,000 additional shares of its common stock. The company will also grant the underwriters an option to purchase an additional 1,320,000 shares and 1,320,000 warrants to cover over-allotments.
Biopure intends to use the net proceeds from the stock offering for general corporate and working capital purposes.
Dawson James Securities, Inc. and Noble International Investments, Inc. are the managing underwriters of the offering, which may be made only by means of the prospectuses and related prospectus supplement. Copies of these documents may be obtained from Dawson James Securities at 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432 and from Noble International Investments at 6501 Congress Avenue, Suite 100, Boca Raton, FL 33487.
Biopure Corporation, headquartered in Cambridge, Mass., develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body’s tissues.
Contact: Douglas Sayles Gerald Ortsman (Investors) Biopure Corporation H.L. Lanzet Inc. (617) 234-6826 (212) 888-4570 IR@biopure.comlanzet@aol.com
Biopure Corporation
CONTACT: Douglas Sayles of Biopure Corporation, +1-617-234-6826,IR@biopure.com; or Gerald Ortsman (Investors), of H.L. Lanzet Inc.,+1-212-888-4570, lanzet@aol.com
Web site: http://www.biopure.com//
Company News On-Call: http://www.prnewswire.com/comp/131224.html/
